Enfusion Inc. logo

Enfusion Inc. (ENFN)

Delisted
17 Apr 2025
NYSE NYSE
$
10. 76
-0.04
-0.3704%
$
955.99M Market Cap
132.86 P/E Ratio
- Div Yield
2.46M Volume
0.22 Eps
$ 10.8
Previous Close
Day Range
10.74 10.87
Year Range
7.83 11.8
Want to track ENFN and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

This company has been delisted from its primary exchange and is no longer publicly traded.
As a result, real-time price data, dividend updates, and corporate disclosures may no longer be available.

ENFN Chart

Clearwater Analytics: 3 Acquisitions That Make This A Strong Buy

Clearwater Analytics: 3 Acquisitions That Make This A Strong Buy

I am upgrading Clearwater Analytics to a 'Strong Buy' due to their strategic acquisitions and robust fundamentals, despite recent stock price fluctuations. Clearwater's acquisition of Enfusion, Beacon, and Bistro significantly enhances their product offerings and positions them as a comprehensive solution provider in the financial software industry. The Enfusion deal, valued at $1.5 billion, adds $200 million ARR and expands Clearwater's capabilities into front office functions, addressing a critical gap.

Seekingalpha | 1 year ago
Enfusion, Inc. (ENFN) Lags Q4 Earnings and Revenue Estimates

Enfusion, Inc. (ENFN) Lags Q4 Earnings and Revenue Estimates

Enfusion, Inc. (ENFN) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.07 per share. This compares to earnings of $0.04 per share a year ago.

Zacks | 1 year ago
Clearwater Analytics' Enfusion Infusion Offers Compelling Value Proposition, Analyst Upgrades Stock

Clearwater Analytics' Enfusion Infusion Offers Compelling Value Proposition, Analyst Upgrades Stock

Piper Sandler analyst Arvind Ramnani upgraded the shares of Clearwater Analytics Holdings Inc CWAN from Neutral to Overweight and raised the price forecast from $28.00 to $36.00.

Benzinga | 1 year ago

Enfusion Inc. (ENFN) FAQ

What does "Delisted" mean?

Enfusion Inc. has been removed from the exchange and is no longer publicly traded.

What was the last recorded dividend?

No dividend payments were recorded prior to delisting.

How long did the company pay dividends?

The company did not have a dividend payment history.

Were there any stock splits?

No stock splits were recorded prior to delisting.

What was the last known trading price?

The stock last traded at $10.76 on Apr 17, 2025 before being delisted.

Enfusion Inc. Profile

- Industry
- Sector
Mr. Oleg Movchan CEO
NYSE Exchange
292812104 CUSIP
US Country
1,102 Employees
- Last Dividend
- Last Split
21 Oct 2021 IPO Date

Overview

Enfusion, Inc. is a leading provider of software-as-a-service (SaaS) solutions tailored for the investment management industry, with a global reach that includes the United States, Europe, the Middle East, Africa, and the Asia Pacific regions. Founded in 1997 and headquartered in Chicago, Illinois, Enfusion assists investment professionals with innovative technology designed to streamline operations, enhance decision-making, and ensure regulatory compliance across multiple asset classes. The company's comprehensive suite of solutions supports the front, middle, and back-office needs, catering to chief investment officers (CIOs), portfolio managers, traders, compliance teams, chief financial officers (CFOs), accountants, and operations teams within the investment management sector.

Products and Services

  • Portfolio Management System - This comprehensive system provides a real-time investment book of record, incorporating valuation and risk tools. It enables CIOs and portfolio managers to view aggregated or decomposed data across their portfolios, facilitating informed decision-making.

    This system is pivotal for tracking investments accurately, assessing portfolio performance, and identifying risk exposures, offering a solid foundation for strategic investment management.

  • Order and Execution Management System - Designed to bridge the gap between portfolio management and the trade execution process, this system streamlines the handling of trade orders across various asset classes. It supports portfolio managers, traders, compliance teams, and analysts in electronically communicating trade orders, managing these orders efficiently, and enforcing trading regulations and internal guidelines.

    The system enhances trading efficiency, minimizes operational risk, and ensures compliance with both internal and regulatory standards.

  • Accounting/General Ledger System - Serving as a real-time accounting book of record, this system is crucial for CFOs, COOs, accountants, and operations teams. It provides comprehensive accounting capabilities, from basic bookkeeping to complex financial reporting, supporting the financial integrity and transparency essential for successful investment management.

    It ensures accurate financial data is always available, thereby supporting strategic financial planning and reporting.

  • Enfusion Analytics System - This powerful analytics platform empowers CIOs, portfolio managers, traders, and analysts to conduct deep dives into portfolio performance across various time horizons. It also facilitates the automation of customized, visualized reports for both internal stakeholders and clients.

    The system's advanced analytical tools help in identifying trends, uncovering insights, and making data-driven decisions to optimize portfolio performance.

  • Technology-powered and Managed Services - Beyond its software offerings, Enfusion provides a range of managed services, leveraging its technology to assist firms in managing their operations more efficiently. These services include but are not limited to, outsourced trade execution, portfolio accounting, and compliance monitoring.

    This comprehensive suite ensures firms can focus on their core competencies and investment strategies, while Enfusion manages the technological and operational complexities.

Contact Information

Address: 125 South Clark Street, Chicago, IL, United States, 60603
Phone: 312 253 9800